CereVasc Announces FDA Approval of Second IDE Study of the eShunt® System
On August 09, 2022, CereVasc, Inc., a privately held, clinical-stage medical device company developing novel, minimally invasive treatments for neurological diseases, announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) application to initiate a pilot trial of the eShunt® System in patients who develop communicating hydrocephalus post aneurysmal subarachnoid hemorrhage (paSAH).
The eShunt System is designed to provide communicating hydrocephalus (CH) patients with the first minimally invasive treatment and an upgrade to the curre...
